Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes

Trial Profile

Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Breast cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 04 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top